Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22179680 | 0.78 | — | — | |
| SCHEMBL1706014 | 0.77 | NOS3 (0.39) | NOS3NOS1NOS2L3MBTL1CYP3A4 | |
| SCHEMBL11547726 | 0.76 | NOS3 (0.42) | NOS3NOS1NOS2L3MBTL1CYP3A4 | |
| SCHEMBL97719 | 0.75 | — | — | |
| SCHEMBL5746657 | 0.74 | HRH3 (0.46) | NOS3NOS1NOS2 | |
| SCHEMBL30764120 | 0.73 | MEN1 (0.30) | — | |
| SCHEMBL30764121 | 0.73 | MEN1 (0.30) | — | |
| SCHEMBL28910743 | 0.73 | MEN1 (0.30) | — | |
| SCHEMBL8207621 | 0.73 | MEN1 (0.30) | — | |
| SCHEMBL16477747 | 0.71 | PTGS1 (0.39) | NOS3NOS1NOS2L3MBTL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459187-B | Janus Kinase Inhibiting Compounds and Methods | HOFFMANN LA ROCHE | 2015-06-17 | — | — | CN | disclosed |
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| CN-102459187-A | Janus Kinase Inhibiting Compounds and Methods | HOFFMANN LA ROCHE | 2012-05-16 | — | — | CN | disclosed |
| EP-2440529-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010142752-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-5270318-A | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-14 | — | — | US | disclosed |
| EP-0533869-A1 | NEMATICIDAL PYRIMDINE DERIVATIVES | ZENECA LIMITED (GB) | 1993-03-31 | — | — | EP | disclosed |
| WO-1992017459-A1 | NEMATICIDAL PYRIMDINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-10-15 | — | — | WO | disclosed |
| EP-0506269-A1 | Nematicide pyrimidine derivatives | ZENECA LIMITED (GB) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | NOS3 900/4885NOS1 894/4885NOS2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.